On Wednesday, October 28, 2026, IQVIA Holdings Inc. reported strong financial results, with both revenue and adjusted diluted earnings per share exceeding the high end of management’s guidance.
Organic growth accelerated across commercial and clinical segments, as rising demand for laboratory services and artificial intelligence acted as significant tailwinds for the firm throughout the recent period.
Driven by solid operational volume, total revenue for the three-month period reached $3.81 billion, representing a 6.9% increase. This performance was supported by the integration of recent strategic acquisitions.
Management raised full-year projections for several key financial metrics. This increase reflects confidence in the ability to maintain a competitive edge in the CRO industry.
Advanced efficiency gains remain a core driver for 2027 and beyond, as the business expects continued momentum due to rising clinical trial demand.